NCT03427554View on ClinicalTrials.gov

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

455

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

January 26, 2018

Study Completion Date

January 26, 2018

Conditions

Acne Vulgaris

Interventions

DRUG

Tretinoin cream 0.1%

Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)

DRUG

RETIN-A® Cream

RETIN-A® (Tretinoin) Cream (Valeant)

DRUG

Vehicle of the test product

Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)

Trial Locations (1)

28217

Catawba Research, LLC, Charlotte

All Listed Sponsors

lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT03427554 - To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter